Source: Biomedicines. Unidade: ICB
Subjects: FARMACOLOGIA, RETÍCULO ENDOPLASMÁTICO, NEOPLASIAS, ENZIMAS OXIRREDUTORAS
ABNT
KHOJAYEVA , Kamilla et al. Targeting the endoplasmic reticulum oxidoreductin-1 alpha–protein disulfide isomerase redox interface as a therapeutic strategy in cancer. Biomedicines, v. 14, 2026Tradução . . Disponível em: https://doi.org/10.3390/biomedicines14020263. Acesso em: 24 abr. 2026.APA
Khojayeva , K., Zhussipbekkyzy, A., Balkybayeva, D., Sabit, K., Lopes, L. R., Sagatbekova, K., et al. (2026). Targeting the endoplasmic reticulum oxidoreductin-1 alpha–protein disulfide isomerase redox interface as a therapeutic strategy in cancer. Biomedicines, 14. doi:10.3390/biomedicines14020263NLM
Khojayeva K, Zhussipbekkyzy A, Balkybayeva D, Sabit K, Lopes LR, Sagatbekova K, Zhakupova A, Aljofan M. Targeting the endoplasmic reticulum oxidoreductin-1 alpha–protein disulfide isomerase redox interface as a therapeutic strategy in cancer [Internet]. Biomedicines. 2026 ; 14[citado 2026 abr. 24 ] Available from: https://doi.org/10.3390/biomedicines14020263Vancouver
Khojayeva K, Zhussipbekkyzy A, Balkybayeva D, Sabit K, Lopes LR, Sagatbekova K, Zhakupova A, Aljofan M. Targeting the endoplasmic reticulum oxidoreductin-1 alpha–protein disulfide isomerase redox interface as a therapeutic strategy in cancer [Internet]. Biomedicines. 2026 ; 14[citado 2026 abr. 24 ] Available from: https://doi.org/10.3390/biomedicines14020263
